Faculty
Oncology Division
Alphabetical list (active faculty):   
Todd A. Fehniger

Todd A. Fehniger, MD, PhD

Professor

Department of Medicine

Oncology Division

Stem Cell Biology

Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Lymphoma
  • Leukemia
  • Immunotherapy
  • Hematopoietic cell transplantation

Research Interests

  • Innate immunity
  • Natural killer cell biology
  • Micro RNAs
  • Cytokines
  • Natural killer cell based therapeutics

Contact

  • 314-747-1385 (office)
  • 314-747-1547 (lab)
  • 314-362-9333 (fax)
  • Division of Oncology
    Mail Stop 8007-0057-06
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 638 Southwest Tower (office)
  • Room 634 Southwest Tower (lab)

Peer-reviewed Articles

  • Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated With Natural Killer Cell Adoptive Therapy
    Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA
    Blood 2021 Nov 19; [Epub ahead of print]
  • Phase I/Dose Expansion Trial of Brentuximab Vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward J, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL
    Blood 2021 Nov 15; [Epub ahead of print]
  • CD7-Deleted Hematopoietic Stem Cells Can Restore Immunity After CAR T Cell Therapy
    Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, DiPersio JF
    JCI Insight 2021 Aug 23;6(16):e149819
  • A Fusion Protein Complex That Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
    Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, Desai S, Neal CC, Pence P, Wong P, Wagner JA, Russler-Germain DA, Zhu X, Spanoudis CM, Gallo VL, Echeverri CA, Ramirez LL, You L, Egan JO, Rhode PR, Jiao JA, Muniz GJ, Jeng EK, Prendes CA, Sullivan RP, Berrien-Elliott MM, Wong HC, Fehniger TA
    Cancer Immunol Res 2021 Sep;9(9):1071-1087
  • Combining AFM13, a Bispecific CD30/CD16 Antibody, With Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-Like Responses Against CD30(+) Malignancies
    Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K
    Clin Cancer Res 2021 Jul 1;27(13):3744-3756
  • Memory-Like Differentiation Enhances NK Cell Responses to Melanoma
    Marin ND, Krasnick BA, Becker-Hapak M, Conant L, Goedegebuure SP, Berrien-Elliott MM, Robbins KJ, Foltz JA, Foster M, Wong P, Cubitt CC, Tran J, Wetzel CB, Jacobs M, Zhou AY, Russler-Germain D, Marsala L, Schappe T, Fields RC, Fehniger TA
    Clin Cancer Res 2021 Sep 1;27(17):4859-4869
  • Reliance on Cox10 and Oxidative Metabolism for Antigen-Specific NK Cell Expansion
    Mah-Som AY, Keppel MP, Tobin JM, Kolicheski A, Saucier N, Sexl V, French AR, Wagner JA, Fehniger TA, Cooper MA
    Cell Rep 2021 Jun 1;35(9):109209
  • Phase I Trial of N-803, an IL15 Receptor Agonist, With Rituximab in Patients With Indolent Non-Hodgkin Lymphoma
    Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA
    Clin Cancer Res 2021 Jun 15;27(12):3339-3350
  • Flow Cytometry-Based Ex Vivo Murine NK Cell Cytotoxicity Assay
    Wong P, Wagner JA, Berrien-Elliott MM, Schappe T, Fehniger TA
    STAR Protoc 2021 Jan 12;2(1):100262
  • Memory-Like Natural Killer Cells for Cancer Immunotherapy
    Gang M, Wong P, Berrien-Elliott MM, Fehniger TA
    Semin Hematol 2020 Oct;57(4):185-193
  • A Pilot Study of Lenalidomide Maintenance Therapy After Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma
    Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, DiPersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2020 Dec;26(12):2223-2228
  • Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations With Response After Adoptive Immunotherapy for Leukemia
    Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Srivatsan SN, Gao F, Romee R, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio J, Fehniger TA
    Cancer Discov 2020 Dec;10(12):1854-1871
  • CAR-Modified Memory-Like NK Cells Exhibit Potent Responses to NK-Resistant Lymphomas
    Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA
    Blood 2020 Nov 12;136(20):2308-2318
  • CD56 Regulates Human NK Cell Cytotoxicity Through Pyk2
    Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott MM, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM
    Elife 2020 Jun 8;9:57346
  • Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity
    Wagner JA, Wong P, Schappe T, Berrien-Elliott MM, Cubitt C, Jaeger N, Lee M, Keppel CR, Marin ND, Foltz JA, Marsala L, Neal CC, Sullivan RP, Schneider SE, Keppel MP, Saucier N, Cooper MA, Fehniger TA
    Cell Rep 2020 Jun 2;31(9):107720
  • Interleukin-15 Superagonist (N-803) Treatment of PML and JCV in a Post-Allogeneic Hematopoietic Stem Cell Transplant Patient
    Oza A, Rettig MP, Powell P, O'Brien K, Clifford DB, Ritchey J, Gehrs L, Hollaway J, Major E, Fehniger TA, Miller CA, Soon-Shiong P, Rock A, DiPersio JF
    Blood Adv 2020 Jun 9;4(11):2387-2391
  • Potently Cytotoxic Natural Killer Cells Initially Emerge From Erythro-Myeloid Progenitors During Mammalian Development
    Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, Wagner JA, Kingsley PD, McGrath KE, Fehniger TA, Palis J, Sturgeon CM
    Dev Cell 2020 Apr 20;53(2):229-239e7
  • Blood Natural Killer Cell Deficiency Reveals an Immunotherapy Strategy for Atopic Dermatitis
    Mack MR, Brestoff JR, Berrien-Elliott MM, Trier AM, Yang TB, McCullen M, Collins PL, Niu H, Bodet ND, Wagner JA, Park E, Xu AZ, Wang F, Chibnall R, Council ML, Heffington C, Kreisel F, Margolis DJ, Sheinbein D, Lovato P, Vivier E, Cella M, Colonna M, Yokoyama WM, Oltz EM, Fehniger TA, Kim BS
    Sci Transl Med 2020 Feb 26;12(532)
  • KIR B Donors Improve the Outcome for AML Patients Given Reduced Intensity Conditioning and Unrelated Donor Transplantation
    Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS
    Blood Adv 2020 Feb 25;4(4):740-754
  • Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies (Second Edition)
    Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M, Almeida LN, Alvisi G, Anderson G, Andra I, Annunziato F, Anselmo A, Bacher P, Baldari CT, Bari S, Barnaba V, Barros-Martins J, Battistini L, Bauer W, Baumgart S, Baumgarth N, Baumjohann D, Baying B, Bebawy M, Becher B, Beisker W, Benes V, Beyaert R, Blanco A, Boardman DA, Bogdan C, Borger JG, Borsellino G, Boulais PE, Bradford JA, Brenner D, Brinkman RR, Brooks AES, Busch DH, Buscher M, Bushnell TP, Calzetti F, Cameron G, Cammarata I, Cao X, Cardell SL, Casola S, Cassatella MA, Cavani A, Celada A, Chatenoud L, Chattopadhyay PK, Chow S, Christakou E, Cicin-Sain L, Clerici M, Colombo FS, Cook L, Cooke A, Cooper AM, Corbett AJ, Cosma A, Cosmi L, Coulie PG, Cumano A, Cvetkovic L, Dang VD, Dang-Heine C, Davey MS, Davies D, De Biasi S, Del Zotto G, Dela Cruz GV, Delacher M, Della Bella S, Dellabona P, Deniz G, Dessing M, Di Santo JP, Diefenbach A, Dieli F, Dolf A, Dorner T, Dress RJ, Dudziak D, Dustin M, Dutertre CA, Ebner F, Eckle SBG, Edinger M, Eede P, Ehrhardt GRA, Eich M, Engel P, Engelhardt B, Erdei A, Esser C, Everts B, Evrard M, Falk CS, Fehniger TA, Felipo-Benavent M, Ferry H, Feuerer M, Filby A, Filkor K, Fillatreau S, Follo M, Forster I, Foster J, Foulds GA, Frehse B, Frenette PS, Frischbutter S, Fritzsche W, Galbraith DW, Gangaev A, Garbi N, Gaudilliere B, Gazzinelli RT, Geginat J, Gerner W, Gherardin NA, Ghoreschi K, Gibellini L, Ginhoux F, Goda K, Godfrey DI, Goettlinger C, Gonzalez-Navajas JM, Goodyear CS, Gori A, Grogan JL, Grummitt D, Grutzkau A, Haftmann C, Hahn J, Hammad H, Hammerling G, Hansmann L, Hansson G, Harpur CM, Hartmann S, Hauser A, Hauser AE, Haviland DL, Hedley D, Hernandez DC, Herrera G, Herrmann M, Hess C, Hofer T, Hoffmann P, Hogquist K, Holland T, Hollt T, Holmdahl R, Hombrink P, Houston JP, Hoyer BF, Huang B, Huang FP, Huber JE, Huehn J, Hundemer M, Hunter CA, Hwang WYK, Iannone A, Ingelfinger F, Ivison SM, Jack HM, Jani PK, Javega B, Jonjic S, Kaiser T, Kalina T, Kamradt T, Kaufmann SHE, Keller B, Ketelaars SLC, Khalilnezhad A, Khan S, Kisielow J, Klenerman P, Knopf J, Koay HF, Kobow K, Kolls JK, Kong WT, Kopf M, Korn T, Kriegsmann K, Kristyanto H, Kroneis T, Krueger A, Kuhne J, Kukat C, Kunkel D, Kunze-Schumacher H, Kurosaki T, Kurts C, Kvistborg P, Kwok I, Landry J, Lantz O, Lanuti P, LaRosa F, Lehuen A, LeibundGut-Landmann S, Leipold MD, Leung LYT, Levings MK, Lino AC, Liotta F, Litwin V, Liu Y, Ljunggren HG, Lohoff M, Lombardi G, Lopez L, Lopez-Botet M, Lovett-Racke AE, Lubberts E, Luche H, Ludewig B, Lugli E, Lunemann S, Maecker HT, Maggi L, Maguire O, Mair F, Mair KH, Mantovani A, Manz RA, Marshall AJ, Martinez-Romero A, Martrus G, Marventano I, Maslinski W, Matarese G, Mattioli AV, Maueroder C, Mazzoni A, McCluskey J, McGrath M, McGuire HM, McInnes IB, Mei HE, Melchers F, Melzer S, Mielenz D, Miller SD, Mills KHG, Minderman H, Mjosberg J, Moore J, Moran B, Moretta L, Mosmann TR, Muller S, Multhoff G, Munoz LE, Munz C, Nakayama T, Nasi M, Neumann K, Ng LG, Niedobitek A, Nourshargh S, Nunez G, O'Connor JE, Ochel A, Oja A, Ordonez D, Orfao A, Orlowski-Oliver E, Ouyang W, Oxenius A, Palankar R, Panse I, Pattanapanyasat K, Paulsen M, Pavlinic D, Penter L, Peterson P, Peth C, Petriz J, Piancone F, Pickl WF, Piconese S, Pinti M, Pockley AG, Podolska MJ, Poon Z, Pracht K, Prinz I, Pucillo CEM, Quataert SA, Quatrini L, Quinn KM, Radbruch H, Radstake TRDJ, Rahmig S, Rahn HP, Rajwa B, Ravichandran G, Raz Y, Rebhahn JA, Recktenwald D, Reimer D, Reis E Sousa C, Remmerswaal EBM, Richter L, Rico LG, Riddell A, Rieger AM, Robinson JP, Romagnani C, Rubartelli A, Ruland J, Saalmuller A, Saeys Y, Saito T, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sandrock I, Santoni A, Sanz RB, Saresella M, Sautes-Fridman C, Sawitzki B, Schadt L, Scheffold A, Scherer HU, Schiemann M, Schildberg FA, Schimisky E, Schlitzer A, Schlosser J, Schmid S, Schmitt S, Schober K, Schraivogel D, Schuh W, Schuler T, Schulte R, Schulz AR, Schulz SR, Scotta C, Scott-Algara D, Sester DP, Shankey TV, Silva-Santos B, Simon AK, Sitnik KM, Sozzani S, Speiser DE, Spidlen J, Stahlberg A, Stall AM, Stanley N, Stark R, Stehle C, Steinmetz T, Stockinger H, Takahama Y, Takeda K, Tan L, Tarnok A, Tiegs G, Toldi G, Tornack J, Traggiai E, Trebak M, Tree TIM, Trotter J, Trowsdale J, Tsoumakidou M, Ulrich H, Urbanczyk S, van de Veen W, van den Broek M, van der Pol E, Van Gassen S, Van Isterdael G, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Borstel A, von Volkmann K, Waisman A, Walker RV, Wallace PK, Wang SA, Wang XM, Ward MD, Ward-Hartstonge KA, Warnatz K, Warnes G, Warth S, Waskow C, Watson JV, Watzl C, Wegener L, Weisenburger T, Wiedemann A, Wienands J, Wilharm A, Wilkinson RJ, Willimsky G, Wing JB, Winkelmann R, Winkler TH, Wirz OF, Wong A, Wurst P, Yang JHM, Yang J, Yazdanbakhsh M, Yu L, Yue A, Zhang H, Zhao Y, Ziegler SM, Zielinski C, Zimmermann J, Zychlinsky A
    Eur J Immunol 2019 Oct;49(10):1457-1973
  • Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes
    Barnell EK, Waalkes A, Mosior MC, Penewit K, Cotto KC, Danos AM, Sheta LM, Campbell KM, Krysiak K, Rieke D, Spies NC, Skidmore ZL, Pritchard CC, Fehniger TA, Uppaluri R, Govindan R, Griffith M, Salipante SJ, Griffith OL
    JCO Clin Cancer Inform 2019 Oct;3:1-12
  • MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells
    Berrien-Elliott MM, Sun Y, Neal C, Ireland A, Trissal MC, Sullivan RP, Wagner JA, Leong JW, Wong P, Mah-Som AY, Wong TN, Schappe T, Keppel CR, Cortez VS, Stamatiades EG, Li MO, Colonna M, Link DC, French AR, Cooper MA, Wang WL, Boldin MP, Reddy P, Fehniger TA
    Immunity 2019 Sep 17;51(3):479-490e6
  • KIR Donor Selection: Feasibility in Identifying Better Donors
    Weisdorf D, Cooley S, Wang T, Trachtenberg E, Haagenson MD, Vierra-Green C, Spellman S, Spahn A, Vogel J, Kobusingye H, Fehninger T, Woolfrey A, Devine S, Ross M, Waller EK, Sobecks R, Parham P, Guethlein LA, Marsh SGE, Miller J
    participating center writing committee

    Biol Blood Marrow Transplant 2019 Jan;25(1):e28-e32
  • A Deep Learning Approach to Automate Refinement of Somatic Variant Calling From Cancer Sequencing Data
    Ainscough BJ, Barnell EK, Ronning P, Campbell KM, Wagner AH, Fehniger TA, Dunn GP, Uppaluri R, Govindan R, Rohan TE, Griffith M, Mardis ER, Swamidass SJ, Griffith OL
    Nat Genet 2018 Dec;50(12):1735-1743
  • Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2018 Feb;59(2):357-362
  • Lenalidomide Consolidation Benefits Patients With CLL Receiving Chemoimmunotherapy: Results for CALGB 10404 (Alliance)
    Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA
    Blood Adv 2018 Jul 24;2(14):1705-1718
  • miR142 Loss-Of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis
    Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley TJ, Maillard I, Reddy PR, Link DC
    Cancer Res 2018 Jul 1;78(13):3510-3521
  • A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients With High-Risk Acute Myeloid Leukemia
    Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E
    Biol Blood Marrow Transplant 2018 Aug;24(8):1581-1589
  • Lenalidomide Results in a Durable Complete Remission in Acute Myeloid Leukemia Accompanied by Persistence of Somatic Mutations and a T-Cell Infiltrate in the Bone Marrow
    Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA
    Haematologica 2018 Jun;103(6):e270-e273
  • First-In-Human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation
    Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA*, Miller JS* (*co-corresponding/senior authors)
    Blood 2018 Jun 7;131(23):2515-2527
  • Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial
    Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA
    Blood 2018 Jan 11;131(2):182-190
  • Glycolytic Requirement for NK Cell Cytotoxicity and Cytomegalovirus Control
    Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA
    JCI Insight 2017 Dec 7;2(23)
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies
    Cossarizza A, Chang HD, Radbruch A, Andra I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Buscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dorner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Forster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, Garcia-Godoy MD, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grutzkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jack HM, Javega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhofer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueroder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mjosberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Muller S, Muller W, Munz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudorfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schuler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J
    Eur J Immunol 2017 Oct;47(10):1584-1797
  • CD56bright NK Cells Exhibit Potent Antitumor Responses Following IL-15 Priming
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA
    J Clin Invest 2017 Nov 1;127(11):4042-4058
  • A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
    Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
    Clin Lymphoma Myeloma Leuk 2017 Jun;17(6):347-353
  • Transcriptional and Post-Transcriptional Regulation of NK Cell Development and Function
    Leong JW, Wagner JA, Ireland AR, Fehniger TA
    Clin Immunol 2017 Apr;177:60-69
  • T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation From Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Single Institution Experience With G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • Recurrent Somatic Mutations Affecting B-Cell Receptor Signaling Pathway Genes in Follicular Lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcgammaRIIIa-Triggered Responses
    Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA
    Biol Blood Marrow Transplant 2017 Mar;23(3):398-404
  • miR-223 Regulates the Number and Function of Myeloid-Derived Suppressor Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
    Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L
    Acta Neuropathol 2017 Jan;133(1):61-77
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Cytomegalovirus Viremia, Disease, and Impact on Relapse in T-Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Longitudinal Body Composition Changes in Diffuse Large B-Cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans
    Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Severe Cytokine-Release Syndrome After T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated With Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of Outcomes After Peripheral Blood Haploidentical Versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia: A Retrospective Single-Center Review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • HLA Disparity Is Not Inconsequential in Peripheral Blood T-Replete Haploidentical Hematopoietic Stem Cell Transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • The IL-15-Based ALT-803 Complex Enhances FcgammaRIIIa-Triggered NK Cell Responses and in Vivo Clearance of B Cell Lymphomas
    Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2016 Feb 1;22(3):596-608
  • Improving Natural Killer Cell Cancer Immunotherapy
    Berrien-Elliott MM, Romee R, Fehniger TA
    Curr Opin Organ Transplant 2015 Dec;20(6):671-680
  • MicroRNA-15/16 Antagonizes Myb to Control NK Cell Maturation
    Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA
    J Immunol 2015 Sep 15;195(6):2806-17
  • Human Cytokine-Induced Memory-Like Natural Killer Cells
    Berrien-Elliott MM, Wagner JA, Fehniger TA
    J Innate Immun 2015;7(6):563-571
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • PTEN Regulates Natural Killer Cell Trafficking in Vivo
    Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA
    Proc Natl Acad Sci U S A 2015 Feb 17;112(7):E700-9
  • Comparative Effectiveness of Anthracycline-Containing Chemotherapy in United States Veterans Age 80 and Older With Diffuse Large B-Cell Lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • MicroRNA Management of NK-Cell Developmental and Functional Programs
    Leong JW, Sullivan RP, Fehniger TA
    Eur J Immunol 2014 Oct;44(10):2862-8
  • Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
    Romee R, Leong JW, Fehniger TA
    Scientifica (Cairo) 2014;2014:205796
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Preactivation With IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-Like Natural Killer Cells
    Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA
    Biol Blood Marrow Transplant 2014 Apr;20(4):463-73
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • MicroRNA-155 Tunes Both the Threshold and Extent of NK Cell Activation Via Targeting of Multiple Signaling Pathways
    Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA
    J Immunol 2013 Dec 15;191(12):5904-13
  • MicroRNA Regulation of Natural Killer Cells
    Sullivan RP, Leong JW, Fehniger TA
    Front Immunol 2013;4:44
  • Lenalidomide-Mediated Enhanced Translation of C/EBPalpha-p30 Protein Up-Regulates Expression of the Antileukemic MicroRNA-181a in Acute Myeloid Leukemia
    Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Blood 2013 Jan 3;121(1):159-69
  • Natural Killer Cell Regulation by MicroRNAs in Health and Disease
    Leong JW, Sullivan RP, Fehniger TA
    J Biomed Biotechnol 2012;2012:632329
  • Cytokine Activation Induces Human Memory-Like NK Cells
    Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA
    Blood 2012 Dec 6;120(24):4751-60
  • MicroRNA-Deficient NK Cells Exhibit Decreased Survival but Enhanced Function
    Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA
    J Immunol 2012 Apr 1;188(7):3019-30
  • T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome
    Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J
    Biol Blood Marrow Transplant 2012 Jun;18(6):937-43
  • A Phase 2 Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • A Phase 2 Study of High-Dose Lenalidomide as Initial Therapy for Older Patients With Acute Myeloid Leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Next-Generation Sequencing Identifies the Natural Killer Cell MicroRNA Transcriptome
    Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER
    Genome Res 2010 Nov;20(11):1590-604
  • Complete Characterization of the MicroRNAome in a Patient With Acute Myeloid Leukemia
    Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, Link DC
    Blood 2010 Dec 9;116(24):5316-5326
  • Limited Engraftment of Low-Risk Myelodysplastic Syndrome Cells in NOD/SCID Gamma-C Chain Knockout Mice
    Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ
    Leukemia 2010 Sep;24(9):1662-4
  • Latent Herpesvirus Infection Arms NK Cells
    White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA
    Blood 2010 Jun 3;115(22):4377-83
  • Granzyme B Is Not Required for Regulatory T Cell-Mediated Suppression of Graft-Versus-Host Disease
    Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ
    Blood 2010 Mar 4;115(9):1669-77
  • Differential Expression of Granzyme B and C in Murine Cytotoxic Lymphocytes
    Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ
    J Immunol 2009 May 15;182(10):6287-97
  • Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients With Isolated Trisomy 13
    Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Blood 2009 Jan 29;113(5):1002-5
  • Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
    Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ
    Immunity 2007 Oct;27(4):635-46
  • Chronic Lymphocytosis of Functionally Immature Natural Killer Cells
    French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
    J Allergy Clin Immunol 2007 Oct;120(4):924-31
  • Acquisition of Murine NK Cell Cytotoxicity Requires the Translation of a Pre-Existing Pool of Granzyme B and Perforin mRNAs
    Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ
    Immunity 2007 Jun;26(6):798-811
  • Hop Cleavage and Function in Granzyme B-Induced Apoptosis
    Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ
    J Biol Chem 2006 Dec 1;281(48):37130-41
  • CD56bright Natural Killer Cells Are Present in Human Lymph Nodes and Are Activated by T Cell-Derived IL-2: A Potential New Link Between Adaptive and Innate Immunity
    Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA
    Blood 2003 Apr 15;101(8):3052-7
  • Postremission Therapy With Low-Dose Interleukin 2 With or Without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients With Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420
    Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
    Clin Cancer Res 2002 Sep;8(9):2812-9
  • In Vivo Evidence for a Dependence on Interleukin 15 for Survival of Natural Killer Cells
    Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA
    Blood 2002 Nov 15;100(10):3633-8
  • Natural Killer Cell Receptors: New Biology and Insights Into the Graft-Versus-Leukemia Effect
    Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA
    Blood 2002 Sep 15;100(6):1935-47
  • Effects of Antibody Concentration on the Separation of Human Natural Killer Cells in a Commercial Immunomagnetic Separation System
    Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ
    Cytometry 2001 Dec 1;45(4):285-93
  • The Biology of Human Natural Killer-Cell Subsets. [Review]
    Cooper MA, Fehniger TA, Caligiuri MA
    Trends Immunol 2001 Nov;22(11):633-40
  • Human Natural Killer Cells: A Unique Innate Immunoregulatory Role for the CD56(Bright) Subset
    Cooper MA*, Fehniger TA*, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (*equal authorship)
    Blood 2001 May 15;97(10):3146-51
  • Interleukin-1beta Costimulates Interferon-Gamma Production by Human Natural Killer Cells
    Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA
    Eur J Immunol 2001 Mar;31(3):792-801
  • Interleukin 15: Biology and Relevance to Human Disease. [Review]
    Fehniger TA, Caligiuri MA
    Blood 2001 Jan 1;97(1):14-32
  • Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype CD8+ T Cells
    Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA
    J Exp Med 2001 Jan 15;193(2):219-31
  • Potential Mechanisms of Human Natural Killer Cell Expansion in Vivo During Low-Dose IL-2 Therapy
    Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA
    J Clin Invest 2000 Jul;106(1):117-24
  • Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN-Gamma Production in Vivo
    Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA
    J Immunol 2000 Feb 15;164(4):1643-7
  • Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation With IL-18 or IL-15 in Combination With IL-12: Implications for the Innate Immune Response
    Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA
    J Immunol 1999 Apr 15;162(8):4511-20
  • Flt3 Ligand Promotes the Generation of a Distinct CD34(+) Human Natural Killer Cell Progenitor That Responds to Interleukin-15
    Yu H*, Fehniger TA*, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA (*equal authorship)
    Blood 1998 Nov 15;92(10):3647-57
  • Natural Killer Cells From HIV-1+ Patients Produce C-C Chemokines and Inhibit HIV-1 Infection
    Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA
    J Immunol 1998 Dec 1;161(11):6433-8
  • Evaluation of Natural Killer Cell Expansion and Activation in Vivo With Daily Subcutaneous Low-Dose Interleukin-2 Plus Periodic Intermediate-Dose Pulsing
    Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA
    Cancer Immunol Immunother 1998 Aug;46(6):318-26
  • Differential Expression and Function of L-Selectin on CD56bright and CD56dim Natural Killer Cell Subsets
    Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS
    J Immunol 1998 Jul 1;161(1):400-8
  • Ultra Low Dose Interleukin-2 Therapy Promotes a Type 1 Cytokine Profile in Vivo in Patients With AIDS and AIDS-Associated Malignancies
    Khatri VP*, Fehniger TA*, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA (*equal authorship)
    J Clin Invest 1998 Mar 15;101(6):1373-8
  • Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells in Vivo
    Fehniger TA, Carson WE, Mrozek E, Caligiuri MA
    Blood 1997 Nov 1;90(9):3647-53
  • CD56bright Natural Killer Cell Subsets: Characterization of Distinct Functional Responses to Interleukin-2 and the c-Kit Ligand
    Carson WE, Fehniger TA, Caligiuri MA
    Eur J Immunol 1997 Feb;27(2):354-60
  • A Potential Role for Interleukin-15 in the Regulation of Human Natural Killer Cell Survival
    Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA
    J Clin Invest 1997 Mar 1;99(5):937-43

Invited Publications and Book Chapters

  • Mystery Solved: IL-15
    Fehniger TA
    J Immunol 2019 Jun 1;202(11):3125-3126
  • Chapter 14: Natural Killer Cells and Innate Lymphoid Cells
    Freud AG, Wagner J, Scoville S, Fehniger TA
    In: Wintrobe’s Hematology, 18th Edition
  • Comment On: Evidence of Innate Lymphoid Cell Redundancy in Humans
    Orange JS, Mace EM, French AR, Yokoyama WM, Fehniger TA, Cooper MA
    Nat Immunol 2018 Aug;19(8):788-789
  • Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory
    Cooper MA, Fehniger TA, Colonna M
    Cold Spring Harb Perspect Biol 2018 Oct 1;10(10)
  • CD70 Turns on NK Cells to Attack Lymphoma
    Fehniger TA
    Blood 2017 Jul 20;130(3):238-239
  • Harnessing NK Cell Memory for Cancer Immunotherapy
    Fehniger TA, Cooper MA
    Trends Immunol 2016 Dec;37(12):877-888
  • Human Adaptive Natural Killer Cells: Beyond NKG2C
    Wagner JA, Fehniger TA
    Trends Immunol 2016 Jun;37(6):351-3
  • Memory NK Cells Take Out the (Mitochondrial) Garbage
    Wagner JA, Fehniger TA
    Immunity 2015 Aug 18;43(2):218-20
  • Chapter 28. Hematologic Malignancies: Chronic Leukemias
    Romee R, Fehniger TA
    In: The Washington Manual of Oncology, 3rd Edition (Govindan R, ed), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2007
  • Extracellular MicroRNAs Turn on NK Cells Via TLR1
    Fehniger TA
    Blood 2013 Jun 6;121(23):4612-3
  • "AbroGATAed" Human NK Cell Development
    Fehniger TA
    Blood 2013 Apr 4;121(14):2579-80
  • Unraveling the Molecular Events Leading to the Genesis of Large Granular Lymphocytic Leukemia Reveals a New Treatment Strategy
    Fehniger TA
    Haematologica 2013 Feb;98(2):159
  • Human NK Cells: SET to Kill
    Leong JW, Fehniger TA
    Blood 2011 Feb 24;117(8):2297-8
  • Chapter 31. Lymphoma
    Fehniger TA
    In: The Washington Manual, Hematology and Oncology Subspecialty Consult, 2nd Edition (Cashen AF, Wildes T, eds), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2008
  • Chapter 28. Hematologic Malignancies: Chronic Leukemias
    Fehniger TA, Welch JS, Pluard TJ
    In: The Washington Manual of Oncology, 2nd Edition (Govindan R, ed), Lippincott, Williams, and Wilkins, Philadelphia, PA, 2007
  • Chapter 12. Murine Cytokine Models and the Genesis of Cancer
    Fehniger TA, Cooper MA, Caligiuri MA
    In: Cytokines in the genesis and treatment of cancer (Caligiuri MA, Lotze MT, eds), Humana Press, Totowa, NJ, 2007
  • Orphan Granzyme Turned Lethal Weapon (Inside Blood)
    Fehniger TA
    Blood 110:475-476, 2007
  • NK Cell and DC Interactions
    Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA
    Trends Immunol 2004 Jan;25(1):47-52
  • Biology and Clinical Impact of Human Natural Killer Cells
    Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA
    Int J Hematol 2003 Jul;78(1):7-17
  • New Directions in Natural Killer Cell-Based Immunotherapy of Human Cancer
    Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA
    Expert Opin Biol Ther 2003 Apr;3(2):237-50
  • Natural Killer Cells: Biology and Application in Stem-Cell Transplantation
    Farag SS, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA
    Cytotherapy 2002;4(5):445-6
  • Interleukin-2 and Interleukin-15: Immunotherapy for Cancer
    Fehniger TA, Cooper MA, Caligiuri MA
    Cytokine Growth Factor Rev 2002 Apr;13(2):169-83
  • Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications
    Fehniger TA, Caligiuri MA
    Int Rev Immunol 2001 Jun;20(3-4):503-34
  • Fatal Leukemia in Interleukin-15 Transgenic Mice
    Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA
    Blood Cells Mol Dis 2001 Jan-Feb;27(1):223-30
  • Cytokine Replacement in Patients With HIV-1 Non-Hodgkin's Lymphoma: The Rationale for Low-Dose Interleukin-2 Therapy
    Shah MH, Baiocchi RA, Fehniger TA, Khatri VP, Gould M, Poiesz B, Bernstein ZP, Caligiuri MA
    Cancer J Sci Am 2000 Feb;6 Suppl 1:S45-51
  • Costimulation of Human Natural Killer Cells Is Required for Interferon Gamma Production
    Fehniger TA, Carson WE, Caligiuri MA
    Transplant Proc 1999 May;31(3):1476-8